Loading startup
Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · Jun 28, 2026, 6:31 PM
What would change this read
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
TL;DR
Seed (YC)Ditto Bio Evolutionary therapies for autoimmune disease.
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2026). Investors: Y Combinator. (High).
Funding
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2026). Investors: Y Combinator. (High).
GitHub
1 GitHub‑linked row(s) (Low).
Product / news
2 product/news‑styled row(s); headline risk without filings (High).
Verified facts
+1 more in Recent movement below
Winter 2026 (W26) batch. Evolutionary intelligence for autoimmune disease using parasite biology.
Weak funding evidence: mention does not include a parsed raise amount/round and may refer to non-funding context.
No open roles indexed yet.
The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.
Source types found
Strongest / recent news-style rows
Wed, May 20, 06:12 PM · confidence 88%high quality
wikipedia · Mon, Jun 29, 05:10 PM · confidence 50%medium quality
wikipedia · Mon, Jun 29, 05:10 PM · confidence 50%medium quality
Newest first · 10 event(s)
Source: Blog
Insights from Ditto Bio on drug discovery and biotechnology.
Source: official_site
Blog | Ditto Bio Publications Blog Blog Learn about our approach to drug discovery and biotechnology. Mapping parasite molecules to treat autoimmune disease March 2, 2026 How we use parasite biology and our MoleculeMapper platform to improve target selection…
Source: official_site
Ditto Bio Publications Blog Check out our first blog here! Backed by Y Combinator Evolutionary therapies for autoimmune disease We discover new drugs by harnessing parasite biology. Contact us Check out our first blog here → The best drugs come from nature. M…
Winter 2026 (W26) batch. Evolutionary intelligence for autoimmune disease using parasite biology.
Source: github_api
AI platform for parasite-derived immunomodulators.
Source: github_api
3 row(s)
The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗Blog | Ditto Bio Publications Blog Blog Learn about our approach to drug discovery and biotechnology. Mapping parasite molecules to treat autoimmune disease March 2, 2026 How we use parasite biology and our MoleculeMapper platform to improve target selection…
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗Ditto Bio Publications Blog Check out our first blog here! Backed by Y Combinator Evolutionary therapies for autoimmune disease We discover new drugs by harnessing parasite biology. Contact us Check out our first blog here → The best drugs come from nature. M…
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗3 row(s)
Third-party press coverage. Independent reporting corroborates company claims; repeated coverage across outlets is a momentum signal.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗AI platform for parasite-derived immunomodulators.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗1 row(s)
Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.
Winter 2026 (W26) batch. Evolutionary intelligence for autoimmune disease using parasite biology.
Why it matters: Funding signal — Pre-Seed per this source; verify against the linked original before relying on it.
Open source ↗2 row(s)
Public engineering activity. Sustained commits, releases, and stars indicate real product development and, for dev tools, developer adoption.
Why it matters: Engineering signal — public repo activity evidences active development and possible developer adoption.
Open source ↗Why it matters: Engineering signal — public repo activity (0 stars, HTML) evidences active development.
Open source ↗1 row(s)
Company blog and newsletters. Shipping cadence and technical depth of posts hint at product velocity and team quality.
Insights from Ditto Bio on drug discovery and biotechnology.
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.